Gabapentin vs Pregabalin for Neuropathic Pain
Pregabalin should be preferred over gabapentin as first-line therapy for neuropathic pain in most clinical situations due to its superior pharmacokinetics, faster titration, more predictable dosing, and comparable efficacy. 1, 2
Key Pharmacokinetic Differences That Drive Clinical Decision-Making
Pregabalin has distinct advantages:
- Linear, first-order absorption with >90% bioavailability regardless of dose, versus gabapentin's saturable absorption that drops from 60% to 33% as doses increase from 900 to 3600 mg/day 2
- Faster onset: Peak plasma concentrations within 1 hour (pregabalin) versus 3-4 hours (gabapentin) 2
- Predictable dose-response: Plasma concentrations increase proportionally with dose, making titration straightforward 1, 2
When to Choose Pregabalin (Most Situations)
Pregabalin is preferred when:
- Rapid pain control is needed - reaches therapeutic levels faster and requires only 4 weeks for adequate trial versus 3-8 weeks for gabapentin titration plus 2 weeks at maximum dose 1
- Simplified dosing is important - twice daily dosing versus three times daily for gabapentin 1
- Patient adherence is a concern - simpler titration schedule improves compliance
- Postherpetic neuralgia (PHN): 62% achieve ≥30% pain relief with pregabalin 600 mg versus 24% placebo (NNT 2.7); 41% achieve ≥50% pain relief versus 15% placebo (NNT 3.9) 3
- Diabetic peripheral neuropathy (DPN): 47% achieve ≥30% pain relief with pregabalin 300 mg versus 42% placebo (NNT 22) 3
When to Choose Gabapentin (Limited Situations)
Gabapentin may be preferred when:
- Cost is the primary barrier - generic gabapentin is significantly less expensive 4
- Lower starting doses are needed - can initiate at 100 mg versus pregabalin's 50-75 mg minimum 1
- Patient has substance abuse history - pregabalin is Schedule V controlled substance in the US; gabapentin has lower abuse potential 1
- Gradual, ultra-slow titration is required - nonlinear pharmacokinetics allow for more granular dose adjustments 1
Dosing Regimens
Pregabalin Dosing 1, 5
- Starting dose: 50 mg three times daily OR 75 mg twice daily
- Initial titration: Increase to 300 mg/day after 3-7 days
- Further titration: Increase by 150 mg/day every 3-7 days as tolerated
- Maximum dose: 600 mg/day (200 mg TID or 300 mg BID)
- Adequate trial duration: 4 weeks
- Note: Doses >300 mg/day not consistently more effective but have higher adverse event rates 1
Gabapentin Dosing 1
- Starting dose: 100-300 mg at bedtime OR 100-300 mg three times daily
- Titration: Increase by 100-300 mg every 1-7 days as tolerated
- Maximum dose: 3600 mg/day in 3 divided doses
- Adequate trial duration: 3-8 weeks for titration PLUS 2 weeks at maximum dose (up to 10 weeks total)
- Critical caveat: Due to saturable absorption, must use three times daily dosing for optimal effect
Renal Dose Adjustments
Both drugs require dose reduction in renal insufficiency and are renally excreted with ~6 hour half-lives 1, 2
Pregabalin Renal Dosing 5
Based on creatinine clearance (CrCl):
- CrCl ≥60 mL/min: Standard dosing (150-600 mg/day)
- CrCl 30-60 mL/min: 75-300 mg/day in 2-3 divided doses
- CrCl 15-30 mL/min: 25-150 mg/day in 1-2 divided doses
- CrCl <15 mL/min: 25-75 mg once daily
- Hemodialysis: Give daily dose based on renal function PLUS supplemental dose immediately after each 4-hour dialysis session
Gabapentin Renal Dosing 1
- Adjust based on CrCl - specific reductions required but dosing more complex due to nonlinear pharmacokinetics
- Hemodialysis patients: Particularly high risk for adverse effects even at low doses 6, 7
Critical Safety Considerations in Renal Impairment
Hemodialysis patients face substantially elevated risks with gabapentinoids 6, 7:
- Gabapentin associated with 50% higher hazard of altered mental status, 55% higher hazard of falls, and 38% higher fracture risk at highest doses 6
- Risk evident even at doses as low as 100 mg/day 6, 7
- Pregabalin associated with 51% higher hazard of altered mental status and 68% higher hazard of falls 6
- Use judiciously in dialysis patients; consider non-gabapentinoid alternatives when possible 6, 7
Adverse Effect Profile (Similar Between Agents)
Common adverse effects (dose-dependent) 1, 5:
- Dizziness: Pregabalin 26-35%, Gabapentin 21-32%
- Somnolence: Pregabalin 16-25%, Gabapentin 12-22%
- Peripheral edema: More common with pregabalin (9-12% at higher doses)
- Weight gain: 4-6% with pregabalin
- Cognitive effects: Confusion, thinking abnormal, ataxia
Serious adverse events are comparable (3-4% for both drugs versus placebo) 8, 3
Efficacy by Condition
Postherpetic Neuralgia
- Both effective - pregabalin shows slightly better NNT (2.7-3.9 vs 5.3-6.7 for gabapentin) 8, 3
- Pregabalin preferred due to faster titration
Diabetic Peripheral Neuropathy
Central Neuropathic Pain
- Pregabalin shows efficacy (NNT 5.9 for ≥30% pain relief) 3
- Limited gabapentin data
HIV Neuropathy
- Neither drug shows benefit - avoid both 3
Mixed/Post-traumatic Neuropathic Pain
- Pregabalin effective (NNT 7.2-8.2) 3
- Limited gabapentin data
Common Pitfalls to Avoid
- Underdosing gabapentin - requires 1800-3600 mg/day for efficacy; many prescribers stop at inadequate doses 1
- Inadequate trial duration - gabapentin requires up to 10 weeks; switching too early misses potential responders 1
- Twice-daily gabapentin dosing - saturable absorption requires TID dosing for optimal effect 1, 2
- Ignoring renal function - failure to adjust doses leads to toxicity, especially altered mental status and falls 6, 7
- Combining gabapentin with pregabalin - no evidence of benefit; increases adverse effects 5
- Expecting universal response - only 3-4 out of 10 patients achieve ≥50% pain relief with either drug 8, 3
Practical Algorithm
For most patients with neuropathic pain:
- Start pregabalin 75 mg BID (or 50 mg TID if elderly/frail)
- Increase to 150 mg BID after 1 week
- If inadequate response after 2-3 weeks, increase to 300 mg BID
- Maximum trial: 4 weeks at optimal dose
Switch to gabapentin if:
- Cost prohibitive
- Substance abuse history
- Pregabalin intolerable or ineffective after adequate trial
For gabapentin:
- Start 100-300 mg at bedtime
- Titrate slowly to 1800-3600 mg/day in 3 divided doses
- Allow 8-10 weeks for adequate trial
In renal impairment (CrCl <60):